Current Infectious Disease Reports

, Volume 9, Issue 1, pp 21–28

Trachoma: Ancient scourge, disease elimination, and future research



Realistically, global elimination of trachoma could not have been considered until the maturation of innovation and public will that converged with the formation of both the Alliance for the Global Elimination of Trachoma by the year 2020 (GET2020) in 1997 and the public-private partnership, the International Trachoma Initiative (ITI) in 1998. Public-private partnerships are cross-sector collaborations that bring heterogeneous capabilities together to work on difficult problems for which the individual partners share common goals. The work of the ITI and partners to date demonstrates that the SAFE strategy reviewed in this article can work, and that it will revolutionize the control of blinding trachoma. Programs working to eliminate trachoma can achieve the GET2020 goals through expanded partnerships, commitment, and research on program integration into evolving health systems.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References and Recommended Reading

  1. 1.
    Kumaresan J: Can blinding trachoma be eliminated by 20/20? Eye 2005, 19:1067–1073.PubMedCrossRefGoogle Scholar
  2. 2.
    Knirsch CA, Mecaskey J, Chami-Khazraji Y, et al.: Trachoma elimination and a public private partnership: The International Trachoma Initiative (ITI). In Proceedings of the 10th International Symposium on Human Chlamydial Infections. Edited by Schachter J, Christiansen G, Clarke IN, et al. San Francisco: International Chlamydia Symposium; 2002:485–494.Google Scholar
  3. 3.
    Mabey D: Chlamydia infections. In Proceedings of the 11th International Symposium on Human Chlamydial Infections. Edited by Chernesky M, Caldwell H, Christiansen G, et al. San Francisco: International Chlamydial Symposium; 2006:315–324.Google Scholar
  4. 4.
    Mabey D, Solomon A, Foster A: Trachoma. Lancet 2003, 362:223–229.PubMedCrossRefGoogle Scholar
  5. 5.
    Rischard JF: High Noon: Twenty Global Problems, Twenty Years to Solve Them. New York: Basic Books; 2002.Google Scholar
  6. 6.
    Reich MR: Public-private partnerships for public health. Nature 2000, 6:617–620.CrossRefGoogle Scholar
  7. 7.
    Hripcsak G, Knirsch CA, Jain N, et al.: A health information network for managing inner-city tuberculosis: bridging clinical care, public health, and home care. Comput Biomed Res 1999 32:67–76.PubMedCrossRefGoogle Scholar
  8. 8.
    Kumaresan JA, Mecaskey JW: The global elimination of blinding trachoma: progress and promise. Am J Trop Med Hyg 2003 69(5 Suppl):24–28.PubMedGoogle Scholar
  9. 9.
    Bailey RL, Arullendran P, Whittle HC, Mabey DC: Randomised controlled trial of single-dose azithromycin in treatment of trachoma. Lancet 1993, 342:453–456.PubMedCrossRefGoogle Scholar
  10. 10.
    Tabbara KF, Abu-el-Asrar A, al-Omar O, et al.: Single-dose azithromycin in the treatment of trachoma. A randomized, controlled study. Ophthalmology 1996, 103:842–846.PubMedGoogle Scholar
  11. 11.
    Dawson CR, Schachter J, Sallam S, et al.: A comparison of oral azithromycin with topical oxytetracycline/polymyxin for the treatment of trachoma in children. Clin Infect Dis 1997, 24:363–368.PubMedGoogle Scholar
  12. 12.
    Schachter J, West SK, Mabey D, et al.: Azithromycin in control of trachoma. Lancet 1999, 354:630–635.PubMedCrossRefGoogle Scholar
  13. 13.
    World Health Organization: Future approaches to trachoma control: report of a global scientific meeting, Geneva, 17–20 June, 1996. Accessed October 10, 2006.
  14. 14.
    Dawson C, Schachter J: Can blinding trachoma be eliminated worldwide? Arch Ophthalmol 1999, 117:974.PubMedGoogle Scholar
  15. 15.
    Ngondi J, Onsarigo A, Matthews F, et al.: Effect of 3 years of SAFE (surgery, antibiotics, facial cleanliness, and environmental change) strategy for trachoma control in southern Sudan: a cross-sectional study. Lancet 2006, 368:589–595.PubMedCrossRefGoogle Scholar
  16. 16.
    Kuper H, Solomon AW, Buchan J, et al.: A critical review of the SAFE strategy for the prevention of blinding trachoma. Lancet Infect Dis 2003, 3:372–381.PubMedCrossRefGoogle Scholar
  17. 17.
    Reacher MH, Munoz B, Alghasany A, et al.: A controlled trial of surgery for trachomatous trichiasis of the upper lid. Arch Ophthalmol 1992, 110:667–674.PubMedGoogle Scholar
  18. 18.
    West S, Munoz B, Lynch M, et al.: Impact of face-washing on trachoma in Kongwa, Tanzania. Lancet 1995, 345:155–158.PubMedCrossRefGoogle Scholar
  19. 19.
    Emerson PM, Cairncross S, Bailey RL, Mabey DC: Review of the evidence base for the ‘F’ and ‘E’ components of the SAFE strategy for trachoma control. Trop Med Int Health 2000, 5:515–527.PubMedCrossRefGoogle Scholar
  20. 20.
    Mecaskey JW, Knirsch CA, Kumaresan JA, Cook JA: The possibility of eliminating blinding trachoma. Lancet Infect Dis 2003, 3:728–734.PubMedCrossRefGoogle Scholar
  21. 21.
    Resnikoff S, Pascolini D, Etya’ale D, et al.: Global data on visual impairment in the year 2002. Bull World Health Organ 2004, 82:844–851.PubMedGoogle Scholar
  22. 22.
    Boost M, Cho P: High incidence of trachoma in rural areas of Guangxi, China. Lancet Infect Dis 2005, 5:735–736.PubMedCrossRefGoogle Scholar
  23. 23.
    Natividad A, Wilson J, Koch O, et al.: Risk of trachomatous scarring and trichiasis in Gambians varies with SNP haplotypes at the interferon-gamma and interleukin-10 loc. Genes Immun 2005, 6:332–340.PubMedCrossRefGoogle Scholar
  24. 24.
    Gradle H: Discussion of Loe.: Sulfanilamide treatment of trachoma. JAMA 1938, 111:1371–1372.Google Scholar
  25. 25.
    Schachter J, Dawson CR: Human Chlamydial Infections. Littleton, MA: PSG Publishing Company; 1978.Google Scholar
  26. 26.
    Frick KD, Lietman TM, Holm SO, et al.: Cost-effectiveness of trachoma control measures: comparing targeted household treatment and mass treatment of children. Bull World Health Organ 2001, 79:201–207.PubMedGoogle Scholar
  27. 27.
    Solomon AW, Holland MJ, Alexander ND, et al.: Mass treatment with single-dose azithromycin for trachoma. N Engl J Med 2004, 351:1962–1971.PubMedCrossRefGoogle Scholar
  28. 28.
    West SK, Munoz B, Mkocha H, et al.: Infection with Chlamydia trachomatis after mass treatment of a trachoma hyperendemic community in Tanzania: a longitudinal study. Lancet 2005, 366:1296–1300.PubMedCrossRefGoogle Scholar
  29. 29.
    Burton MJ, Holland MJ, Makalo P, et al.: Re-emergence of Chlamydia trachomatis infection after mass antibiotic treatment of a trachoma-endemic Gambian community: a longitudinal study. Lancet 2005, 365:1321–1328.PubMedCrossRefGoogle Scholar
  30. 30.
    Chidambaram JD, Alemayehu W, Melese M, et al.: Effect of a single mass antibiotic distribution on the prevalence of infectious trachoma. JAMA 2006, 295:1142–1146.PubMedCrossRefGoogle Scholar
  31. 31.
    Hotez PJ, Molyneux DH, Fenwick A, et al.: Incorporating a rapid-impact package for neglected tropical diseases with programs for HIV/AIDS, tuberculosis, and malaria. PLoS Med 2006, 3(e102):576–584.Google Scholar
  32. 32.
    Wright HR, Keeffe JE, Taylor HR: Trachoma and the need for a coordinated community-wide response: a case-based study. PLoS Med 2006, 3(e41):186–190.Google Scholar
  33. 33.
    Leach AJ, Shelby-James TM, Mayo M, et al.: A prospective study of the impact of community-based azithromycin treatment of trachoma on carriage and resistance of Streptococcus pneumoniae. Clin Infect Dis 1997, 24:356–362.PubMedGoogle Scholar
  34. 34.
    Fry AM, Jha HC, Lietman TM, et al.: Adverse and beneficial secondary effects of mass treatment with azithromycin to eliminate blindness due to trachoma in Nepal. Clin Infect Dis 2002, 35:395–402.PubMedCrossRefGoogle Scholar
  35. 35.
    Whitty CJ, Glasgow KW, Sadiq ST, et al.: Impact of community-based mass treatment for trachoma with oral azithromycin on general morbidity in Gambian children. Pediatr Infect Dis J 1999, 18:955–958.PubMedCrossRefGoogle Scholar
  36. 36.
    Batt SL, Charalambous BM, Solomon AW, et al.: Impact of azithromycin administration for trachoma control on the carriage of antibiotic resistant Streptococcus pneumoniae. Antimicrob Agents Chemother 2003, 47:2765–2769.PubMedCrossRefGoogle Scholar
  37. 37.
    Solomon AW, Mohammed Z, Massae PA, et al.: Impact of mass distribution of azithromycin on the antibiotic susceptibilities of ocular Chlamydia trachomatis. Antimicrob Agents Chemother 2005, 49:4804–4806.PubMedCrossRefGoogle Scholar
  38. 38.
    Somani J, Bhullar VB, Workowski KA, et al.: Multiple drug-resistant Chlamydia trachomatis associated with clinical treatment failure. J Infect Dis 2000, 181:1421–1427.PubMedCrossRefGoogle Scholar
  39. 39.
    West SK, West ES, Alemayehu W, et al.: Single-dose azithromycin prevents trichiasis recurrence following surgery: randomized trial in Ethiopia. Arch Ophthalmol 2006, 124:309–314.PubMedCrossRefGoogle Scholar
  40. 40.
    Burton MJ, Kinteh F, Jallow O, et al.: A randomised controlled trial of azithromycin following surgery for trachomatous trichiasis in the Gambia. Br J Ophthalmol 2005, 89:1282–1288.PubMedCrossRefGoogle Scholar
  41. 41.
    Gray RH, Wabwire-Mangen F, Kigozi G, et al.: Randomized trial of presumptive sexually transmitted disease therapy during pregnancy in Rakai, Uganda. Am J Obstet Gynecol 2001, 185:1209–1217.PubMedCrossRefGoogle Scholar
  42. 42.
    Workowski KA, Berman SM: Sexually transmitted diseases treatment guidelines, 2006. MMWR Recomm Rep 2006, 55(RR-11):1–94.PubMedGoogle Scholar
  43. 43.
    Baral K, Osaki S, Shreshta B, et al.: Reliability of clinical diagnosis in identifying infectious trachoma in a low-prevalence area of Nepal. Bull World Health Organ 1999, 77:461–466.PubMedGoogle Scholar
  44. 44.
    Michel CE, Solomon AW, Magbanua JP, et al.: Field evaluation of a rapid point-of-care assay for targeting antibiotic treatment for trachoma control: a comparative study. Lancet 2006, 367:1585–1590.PubMedCrossRefGoogle Scholar
  45. 45.
    Myatt M, Mai NP, Quynh NQ, et al.: Using lot quality-assurance sampling and area sampling to identify priority areas for trachoma control: Viet Nam. Bull World Health Organ 2005, 83:756–763.PubMedGoogle Scholar
  46. 46.
    Crane DD, Carlson JH, Fischer ER, et al.: Chlamydia trachomatis polymorphic membrane protein D is a species-common pan-neutralizing antigen. Proc Natl Acad Sci U S A 2006, 103:1894–1899.PubMedCrossRefGoogle Scholar
  47. 47.
    Ellis JJ: Founding Brothers: The Revolutionary Generation. New York: Random House; 2000.Google Scholar
  48. 48.
    Barr RG, Diez-Roux AV, Knirsch CA, Pablos-Mendez A: Neighborhood poverty and the resurgence of tuberculosis in New York City, 1984–1992. Am J Public Health 2001, 91:1487–1493.PubMedCrossRefGoogle Scholar
  49. 49.
    Sachs J: The End of Poverty. New York: Penguin Books; 2005.Google Scholar

Copyright information

© Current Medicine Group LLC 2007

Authors and Affiliations

  1. 1.Clinical Research and Development, Pfizer Inc., and College of Physicians and SurgeonsColumbia UniversityNew YorkUSA

Personalised recommendations